Knowledge graph · Trial
Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus
COMPLETED
- Identifier
- CI-TRIAL-00016181
- Entity page
- /trial/NCT01238042 ↗
- Edges
- 1
- Neighbours
- 1 cancers
- Drawn
- 1 of 1 neighbours (cap 60); table lists every fetched edge
Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.
Most connectedLung Non-Small Cell Carcinoma 3,147Malignant Colorectal Neoplasm 1,866ABL1 298EGFR 276Imatinib 450Dasatinib 321
Neighbourhood
Radial view
Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.
Edges
Every edge, grouped by relationship
Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.
| Relationship | Neighbour | Direction | Evidence level | Cancer context | Support | Claim | Source | Expand |
|---|---|---|---|---|---|---|---|---|
| Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus condition of …CONDITION_OFderived1 of 1 | ||||||||
| ← condition of | Carcinoma In Situ registry condition “CIS” mapped ALIAS | — | — | Carcinoma In Situ | 1 | Observed | clinicaltrials | graph → |
An edge is a relationship stated by a source (CIViC evidence item, ChEMBL indication or mechanism, openFDA approval) and kept with its native evidence level, direction and cancer context — CancerIndex never infers, merges or re-scales it. Rows marked derived are counts and measurements read from registries (ClinicalTrials.gov conditions and interventions, GDC/cBioPortal cohort frequencies ≥ 5 % with ≥ 20 cases affected, regulatory approval records): they say how often two entities co-occur in a registry, not that a source asserted a biological or clinical link. Trials are rolled up over the cancer and its descendants; approvals list authority, jurisdiction and date as published.